NCT05335005

MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)

A Study to Evaluate Safety and Tolerability of Co-administration of MK-2060 and Clopidogrel in Participants With End-Stage Renal Disease on Hemodialysis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

MK-2060 is being developed for prevention of thrombotic complications in end-stage renal disease (ESRD). The purpose of this study is to conduct a preliminary evaluation of the safety and tolerability of MK-2060 treatment in combination with a commonly used P2Y12 receptor inhibitor, clopidogrel, in ESRD patients.

Conditions

• End-Stage Renal Disease
• Kidney Failure, Chronic

Interventions

Type	Name	Description
DRUG	MK-2060	MK-2060 administered via IV infusion

Timeline

• Start date: 2022-05-30
• Primary completion: 2023-02-14
• Completion: 2023-02-14
• First posted: 2022-04-19
• Last updated: 2024-10-17
• Results posted: 2024-10-17

Locations

3 sites across 3 countries: United States, Israel, Romania

Regulatory

• FDA-regulated drug study